# **HPV Primary Screening project**

**Development of the new NCSP Register** 



**NCPTS National Training Day** 

New Zealand Government

The National Cervical Screening Programme (NCSP) is changing the way cervical screening is undertaken in New Zealand.
From July 2023 the primary test for cervical screening will change to a human papillomavirus (HPV) test.



#### Changing the future of cervical screening

- From July 2023 the primary test for cervical screening will change to a human papillomavirus (HPV) test.
- This new screening method will test for the presence of HPV, the cause for 99% of cervical cancers.
- Self-testing with clinical oversight will be an option for all wāhine/whānau
- The screening interval following a negative test will change to 5 years

#### **Guiding principles**

- Deliver a best practice National Cervical Screening Programme
- Improve equitable access to screening for all population groups
- Be acceptable to people, Wāhine and Whānau
- Maintain and improve safety and quality of screening
- Maintain a skilled and competent workforce to deliver the programme
- Maintain and improve the NCSP Register's capability to support the programme

Screening seeks to detect abnormalities in apparently healthy individuals so that serious illness or disease can be prevented.



#### **Critical drivers for change**


Our aim is to **detect changes** to cervical cells while they can be treated and **before** they cause **cancer**.

- Improved health outcomes
- Reduced inequalities in access and outcome
- Improved programme performance
- Improved patient experience
- Reduced cost and burden to the health system

#### **HPV Screening options: Self-test**

- HPV self-taken sample
- Lower vaginal swab
- Requires informed consent process with clinical oversight
- If HPV detected a clinician taken sample is required





#### **HPV Screening options: Clinician**

- HPV swab, taken by clinician
- Speculum sample from cervix can be requested
- If HPV detected reflex cytology test determines cell changes





#### New clinical management pathway

#### **Self taken sample**

- HPV not detected 5 year screening interval
- HPV 16/18 detected
   Option of direct referral to colposcopy without cytology triage
- HPV other type detected
   Cytology triage reqd
   HSIL colposcopy
   LSIL repeat in 12 months

#### **Clinician taken sample**

- HPV not detected 5 year screening interval
- HPV any type detected
  Reflex cytology shows:
  HSIL colposcopy
  LSIL repeat in 12 months



The clinical management pathway will change to reflect HPV Primary Screening. It will be determined by cytology triage.

#### **Empowering wahine with choice**

Self-testing is not the only option available from July 2023, participants, wāhine and whānau have choices.

- ✓ Choose to **self-test**, in a **location** of their choice
- ✓ Opt for a clinician to take the HPV test swab
- ✓ Choose for the clinician to take a combined HPV and cytology test



To enable HPV Primary Screening, a new NCSP Register will be implemented. The new Register will be a population based register sourced from NHI with opt-off option.



#### The new NCSP Register

- New technology platform
- Population based sourced from NHI
- Improved functionality
- Centralised notification and recall
- Enhanced monitoring and reporting
- Increased capacity for user access

#### **Centralised notification from the Register**

- Centralised notification direct to all eligible participants
- Participants notified they are due for screening letter, text or email
- They will be directed to available providers in their local area
- Reporting to Primary Care and sample-takers will advise who has been notified
- An opt-off option will be available to participants

# **Driving for equity**

- The new Register creates a data warehouse for the NCSP to analyse trends and statistics
- Will provide critical insights into screening
- Shows us where more facilities or resource is needed
- Allows us to shape more focused campaigns to increase screening participation
- Capability to future proof for new enhancements and requirements
  - other screening details, immunisation

### **Building the new NSCP Register**

- The technology build kicked off in July 2022
- Working in partnership with Deloitte
- Sector requirements are informing the design
- Technology development over the next 8 months
- Testing approach
- Data migration strategy
- Cutover to Go Live

# **Laboratory interaction with the Register**

- Improved access and authentication through web browser, username and password
- Lab users will have access to the person records including all tests submitted, letters sent, notes and any contacts made with the person
- Other functionality will include various reports and dashboards which use real-time data
- HL7 Client will still be required to send test results to the new Register we anticipate existing processes to remain the same
- When test results are sent to the new Register, the Register will provide acknowledgement or error messages back to the labs

# Laboratory performance monitoring

The way laboratory performance is monitored will be reviewed as there is some duplication currently.

- ✓ Contract reporting information that can be obtained from the new Register will not need to be requested from Labs
- ✓ Monitoring information obtained from the NCSP Register will be sent to laboratories using the NCSP Laboratory 6-monthly Report
- ✓ Laboratory Key Performance Indictors will be reviewed

### **Updating the laboratory request form**

- New electronic request form
- The request form will be used for HPV testing, cytology and histology
- Auto-populated form based on NHI
- Will flow directly into the laboratory LIS and though into reports
- Implementation is likely to be staggered based on IT capability
- We are aiming to release this in 2023

### Implications for laboratories

- Expected increase in sample numbers
- New ways of handling large numbers of swab samples will be needed
- A comprehensive education programme is needed for providing correct recommendations on next steps for participants with abnormal results
- Understand and adopt technology and reporting changes with the new Register
- Transition requirements will be agreed and placed into contractual arrangements
- Transition support will be in place for each laboratory in the lead up to, and post, the changes

The Laboratory Working Group will provide expert advice, guidance and advocacy to ensure the successful transition from cytology screening to HPV primary screening.

This includes changes to laboratory practice, laboratory technology, technical interfaces, coding, NSCP Policies and Standards (Section 5) and education and training needs for laboratories.



# Questions



#### Staying in touch

We are committed to keeping you updated as the project progresses. We will be in touch with you regularly, and there will be opportunities for you to be part of helping to implement these changes.
 We want this to work for you, and for all wahine and whanau.



HPVscreen@health.govt.nz

You are important to us. Please get in touch if you have any **questions** or **feedback**.



<u>Cervical screening | Time to Screen - National Screening Unit</u>

National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

HPV primary screening | National Screening Unit (nsu.govt.nz)